What is the recommended workup to diagnose neuromyelitis optica (NMO)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Workup to Diagnose Neuromyelitis Optica

The diagnostic workup for neuromyelitis optica (NMO) requires serum AQP4-IgG antibody testing via cell-based assay as the cornerstone test, combined with MRI of brain, orbits, and entire spinal cord, plus CSF analysis to exclude alternative diagnoses and assess for characteristic features. 1

Essential Serologic Testing

Test for AQP4-IgG antibodies using cell-based assays (immunofluorescence or flow cytometry) - this is the gold standard and most specific test for NMOSD. 2, 1 Cell-based assays are mandatory because older ELISA methods using denatured antigens have poor sensitivity and specificity. 3

  • If AQP4-IgG is negative but clinical suspicion remains high, test for MOG-IgG antibodies using cell-based assays with full-length human MOG protein. 3 This distinguishes MOG-encephalomyelitis from true NMOSD, which has different treatment implications.
  • Use Fc-specific or IgG1-specific secondary antibodies to avoid cross-reactivity with IgM and IgA. 3
  • Test serum, not CSF - serum has higher sensitivity for both antibodies. 3

Neuroimaging Protocol

Obtain MRI of the entire neuraxis with gadolinium:

Spinal Cord MRI (Sagittal and Axial)

  • Look for longitudinally extensive transverse myelitis (LETM) - contiguous lesions extending ≥3 vertebral segments. 1, 4 This is highly characteristic of NMOSD.
  • Central cord involvement with T2 hyperintensity occupying >50% of cross-sectional area. 1
  • Conus medullaris lesions are particularly suggestive. 3
  • Bright spotty lesions on T2 imaging.
  • Longitudinally extensive spinal cord atrophy in patients with prior myelitis. 3

Brain and Orbital MRI

  • Optic nerve imaging: Look for longitudinally extensive optic nerve lesions (>1/2 the length of pre-chiasmal nerve), posterior optic nerve involvement extending to chiasm, and perioptic gadolinium enhancement. 3 Median lesion length in NMO is 23.1 mm versus 9.9 mm in MS. 3
  • Brain lesions occur in up to 60% of NMOSD patients and do NOT exclude the diagnosis. 5 Characteristic patterns include:
    • Area postrema (dorsal medulla) lesions
    • Periependymal lesions around third/fourth ventricles and aqueduct
    • Diencephalic lesions (hypothalamus, thalamus)
    • Large, confluent hemispheric lesions
    • Corticospinal tract lesions
  • Absence of MS-typical features: No Dawson's fingers, no juxtacortical U-fiber lesions, no ovoid periventricular lesions. 3 These findings argue against NMOSD.

Brain MRI Red Flags Against NMOSD

The Matthews-Jurynczyk criteria help distinguish from MS: absence of lesions adjacent to lateral ventricles that are ovoid/round or associated with inferior temporal lobe lesions, and absence of Dawson's finger-type or juxtacortical U-fiber lesions. 3

Cerebrospinal Fluid Analysis

Perform lumbar puncture for:

  • Cell count and differential: Pleocytosis >50 cells/μL or neutrophilic pleocytosis (>5% neutrophils) supports NMOSD over MS. 3, 1
  • Oligoclonal bands (OCBs): Absence of CSF-restricted OCBs supports NMOSD (present in <20-30% of NMOSD versus >90% of MS patients). 3, 4 Use isoelectric focusing for detection.
  • Protein: Often elevated during acute attacks.
  • Exclude infectious/inflammatory mimics (VDRL, ACE, cytology).

Ophthalmologic Evaluation

  • Fundoscopy during acute optic neuritis: Look for prominent papilledema/papillitis/optic disc swelling - more severe than typical MS-related optic neuritis. 3
  • Optical coherence tomography (OCT): Assess retinal nerve fiber layer thickness to document optic nerve damage. 5
  • Visual evoked potentials (VEP): Document demyelination in patients with history of optic neuritis. 3

Clinical Features That Trigger Testing

Test for NMOSD when patients present with:

  • Simultaneous bilateral acute optic neuritis 3
  • Severe visual deficit/blindness in one or both eyes during acute ON 3
  • Recurrent optic neuritis with unusually high frequency 3
  • Severe or frequent myelitis episodes 3
  • Permanent sphincter/erectile dysfunction after myelitis 3
  • Area postrema syndrome: Intractable nausea, vomiting, or hiccups 3
  • Acute respiratory insufficiency with brainstem lesions 3
  • Steroid-dependent symptoms or frequent flare-ups after methylprednisolone 3
  • Worsening on MS therapies (interferon-beta, natalizumab) 3

Diagnostic Criteria Application

For AQP4-IgG-positive NMOSD: Requires positive serology plus ≥1 core clinical characteristic (optic neuritis, acute myelitis, area postrema syndrome, acute brainstem syndrome, symptomatic narcolepsy/diencephalic syndrome, or symptomatic cerebral syndrome with NMOSD-typical brain lesions). 1

For AQP4-IgG-negative NMOSD: Requires ≥2 core clinical characteristics from separate attacks, with ≥1 being optic neuritis, myelitis with LETM, or area postrema syndrome, PLUS dissemination in space (≥2 different core clinical characteristics) AND specific MRI requirements. 1 This diagnosis is more stringent and requires excluding MOG-IgG positivity.

Critical Pitfalls to Avoid

  • Do not wait for antibody results to treat acute attacks - start high-dose IV methylprednisolone immediately and consider early plasma exchange for severe or steroid-refractory cases. 2, 6
  • Do not use older ELISA-based antibody tests - they have unacceptable false positive and false negative rates. 3
  • Do not exclude NMOSD based on normal brain MRI - 40% have normal brain imaging initially. 3
  • Do not exclude NMOSD based on short spinal cord lesions - 44-52% of MOG-EM patients have short lesions at some point. 3
  • Do not restrict testing only to patients meeting AQP4-IgG-negative NMOSD criteria - this misses many MOG-EM patients with isolated syndromes. 3

References

Related Questions

Can optic neuromyelitis (neuromyelitis optica spectrum disorder) cause sinusoidal obstruction syndrome?
What is the risk of neuromyelitis optica in patients with other autoimmune diseases, and which comorbid autoimmune conditions are most commonly associated?
Is Hashimoto's thyroiditis associated with neuromyelitis optica spectrum disorder (NMOSD)?
Can you provide ten references to consensus guidelines or recommendations for managing neuromyelitis optica spectrum disorder (NMOSD)?
How is area postrema syndrome diagnosed and managed, including workup for neuromyelitis optica spectrum disorder?
An 80-year-old male patient taking trazodone 50 mg and melatonin 12 mg nightly continues to report inability to sleep; what medication should be prescribed?
What chemotherapy regimen should be administered concurrently with radiation therapy for cervical cancer, and what alternatives are available if cisplatin is contraindicated?
How should methylprednisolone be dosed in a child with an acute inflammatory condition, including weight‑based dosing and maximum daily limits?
Can iron bisglycinate cause black stools?
What should be documented in the clinical note to obtain approval for a powered stair lift for a ≥70‑year‑old patient with gait instability and lower‑extremity weakness from osteoarthritis and prior ischemic stroke, who ambulates with a cane, cannot safely use a straight standard‑rise staircase, and has recent falls including a wrist fracture?
For an 83‑year‑old patient with blood pressure now 120‑130/80‑90 mm Hg after increasing telmisartan to 80 mg daily one month ago, should I continue this dose?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.